Helena Engman
Helena Engman has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alastair M. Mathewson
Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
1 shared publication Anders Borde
Global Product Development, Pharmaceutical Technology & Development, Operations
1 shared publication- Andy Sykes
DMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
1 shared publication - Bertil Abrahamsson
Global Product Development, Pharmaceutical Technology & Development, Operations
1 shared publication - Bistra Kirova
Oncology Patient Safety, Oncology R&D AstraZeneca Cambridge UK
1 shared publication - Chris Roe
Quotient Sciences Nottingham UK
1 shared publication
Latest Publications
- Open Access
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open AccessOpen‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- 22 September 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (10) , 6203-6214
Leveraging Biopharmaceutics Bridging Risk Assessment and In Vivo Predictive Tools to Accelerate Immediate Release Drug Product Development by Minimized Need for Clinical Bridging Studies
Accelerated development of oral solid dosage forms necessitates effective strategies to link clinical data across development stages. Emerging predictive tools present a viable alternative, ensuring targeted clinical performance with a significantly reduced dependence on traditional clinical bridging studies. This paper introduces a biopharmaceutics bridging risk assessment (BBRA) tool that extends opportunities to avoid clinical bridging studies beyond the biopharmaceutics classification system (BCS) classes 1 and 3, utilizing physiologically based biopharmaceutics modeling (PBBM) and advanced in vitro tools (such as the TNO (Netherlands Organisation for Applied Scientific Research) transit intestinal model, TIM). PBBM uses experimental solubility, dissolution, and permeability input, validated by clinical data, to enhance risk assessment granularity and understanding, while TIM uniquely simulates physiological gastrointestinal conditions, complementary to traditional dissolution tests. The decision-tree framework, aligned with ICH M9 principles, supports iterative decision-making across the drug development life cycle, from preclinical to postapproval phases. An analysis of 32 AstraZeneca bridging cases showed that application of BBRA could reduce the number of clinical studies by 70%. By leveraging in vivo predictions and comprehensive clinical insights, our strategic approach mitigates late-stage BE failure risks, expedites market introduction, and ensures effective patient treatments.
- 22 September 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (10) , 6203-6214
Leveraging Biopharmaceutics Bridging Risk Assessment and In Vivo Predictive Tools to Accelerate Immediate Release Drug Product Development by Minimized Need for Clinical Bridging Studies
Accelerated development of oral solid dosage forms necessitates effective strategies to link clinical data across development stages. Emerging predictive tools present a viable alternative, ensuring targeted clinical performance with a significantly reduced dependence on traditional clinical bridging studies. This paper introduces a biopharmaceutics bridging risk assessment (BBRA) tool that extends opportunities to avoid clinical bridging studies beyond the biopharmaceutics classification system (BCS) classes 1 and 3, utilizing physiologically based biopharmaceutics modeling (PBBM) and advanced in vitro tools (such as the TNO (Netherlands Organisation for Applied Scientific Research) transit intestinal model, TIM). PBBM uses experimental solubility, dissolution, and permeability input, validated by clinical data, to enhance risk assessment granularity and understanding, while TIM uniquely simulates physiological gastrointestinal conditions, complementary to traditional dissolution tests. The decision-tree framework, aligned with ICH M9 principles, supports iterative decision-making across the drug development life cycle, from preclinical to postapproval phases. An analysis of 32 AstraZeneca bridging cases showed that application of BBRA could reduce the number of clinical studies by 70%. By leveraging in vivo predictions and comprehensive clinical insights, our strategic approach mitigates late-stage BE failure risks, expedites market introduction, and ensures effective patient treatments.